In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eli Lilly & Co.

www.lilly.com

Latest From Eli Lilly & Co.

Lilly Advances IL-23, Gastroenterology Ambitions With Mirikizumab In Crohn's Disease

The company reported positive Phase II results and will move its potential fourth-to-market IL-23 inhibitor into Phase III in Crohn's disease later this year. Mirikizumab – in Phase III for psoriasis and ulcerative colitis – may be the second IL-23 drug for an IBD indication.

Clinical Trials Gastrointestinal

Deal Watch: Ireland's Amryt Acquires Aegerion

European firms Amryt and Evotec have signed agreements to acquire two companies based across the Atlantic – Aegerion and Just Biotherapeutics, respectively. 

Deals M & A

What We Learned From Q1 Pharma Earnings Season

With US drug pricing pressures and generic and biosimilar competition weighing on big pharma, new launches and brisk business in China have been providing a silver lining. Scrip writers analyze the industry landscape in light of the first-quarter results.

Sales & Earnings Companies

Keeping Track: Resubmissions For Tlando And Twirla NDAs, And A BTD For Pomalyst

The latest drug development news and highlights from our US FDA Performance Tracker.
US FDA Performance Tracker Drug Review
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register